Canagliflozin use in Type I diabetes mellitus

Postgraduate Medicine

Volumn 129, Issue 3, 2017, Pages 336-339

  Guthrie, Robert ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

canagliflozin; diabetic ketoacidosis; ketosis; SGLT 2 inhibitors; Type 1 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

ARTICLE; CLINICAL RESEARCH; DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INSURANCE; KETOACIDOSIS; LATENT AUTOIMMUNE DIABETES IN ADULTS; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN ATTITUDE; SCIENTIFIC LITERATURE; TREATMENT OUTCOME;

CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85002271265     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2017.1264855     Document Type: Article

References (12)

1. Nair S, Wilding JPH., Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endo and Metab. 2010;34(1):34–42.
2. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14:539–545.
3. Invokana Package Insert; Raritan NJ. Janssen Pharmaceuticals; 2016.
4. Jardiance Package Insert; Ridgefield CT. Boehringer/Ingelheim Pharmaceuticals; 2016.
5. Farxiga Package Insert; Wilmington DE. AstraZeneca Pharmaceuticals; 2016.
6. Atkinson MA, Von herrath M, Powers C, et al. Current concepts on the pathogenesis of type 1 diabetes–considerations for attempts to prevent and reverse the Disease. Diabetes Care. 2015;38(6):979–988.
7. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis:a potential complication of treatment with sodium-glucose cotransporter 2 Inhibition. Diabetes Care. 2015;38:1687–1693.
8. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680–1686.
9. Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258–2265.
10. Perkins BA, Cherney DZI, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes:results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480–1483.
11. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
12. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334. DOI:10.1056/NEJMoa1515920.